INTEGRATIVE GENOMICS #10



LETS GET STARTED





AGENDA

- **12:30 12:45** Recap [Germline cancer genomics]
- **12:45 13:00** Break + questions
- **13:00 13:30** Lecture 1 [*Integrative genomics*]
- **13:30 13:40** Break
- **13:40 14:00** Discussion of article [*Multi-omic prediction of incident type 2 diabetes*]
- **14:00 14:20** Lecture 2 [Multimodal data integration]
- **14:20 14:30** Break
- **14:30 15:45** Group work + presentation
- 15:45 16:00Evaluation at Moodle

AGENDA

12:30 – 12:45 Recap [Germline cancer genomics]

- **12:45 13:00** Break + questions
- **13:00 13:30** Lecture 1 [*Integrative genomics*]
- **13:30 13:40** Break
- **13:40 14:00** Discussion of article [*Multi-omic prediction of incident type 2 diabetes*]
- **14:00 14:20** Lecture 2 [*Multimodal data integration*]
- **14:20 14:30** Break
- **14:30 15:45** Group work + presentation
- **15:45 16:00** Evaluation at Moodle



RARE CANCER MUTATIONS

Classic BRCA1 Pedigree



- Inherited driver mutations include BRCA1/2 and APC
- Nearly 10% of cancers are inherited
- Autosomal dominant pattern with incomplete penetrance
- Presents early and bilaterally
- BRCA1/2 follow the "two-hit" hypothesis
- Inherited cancers are recessive at the cellular level but dominant at the individual level





COMMON CANCER MUTATIONS

- Common variants are not strong enough to be considered driver mutations
- Identified by GWAS
- Identification of common SNPs relies on
 - sample size
 - allele frequency
 - effect size
 - phenotypic clarity
- Heritability estimates range from 4-26%
- Strength of PGS will vary between cancers



COMBINING CANCER MUTATIONS



AALBORG UNIVERSITY

BREAK + QUESTIONS

AGENDA

- **12:30 12:45** Recap [Germline cancer genomics]
- **12:45 13:00** Break + questions
- **13:00 13:30** Lecture 1 [*Integrative genomics*]
- **13:30 13:40** Break
- **13:40 14:00** Discussion of article [*Multi-omic prediction of incident type 2 diabetes*]
- **14:00 14:20** Lecture 2 [*Multimodal data integration*]
- **14:20 14:30** Break
- **14:30 15:45** Group work + presentation
- **15:45 16:00**Evaluation at Moodle



INTEGRATIVE GENOMICS

integrative

adjective

UK ◀ŷ /'ın.tə.grə.tıv/ US ◀ŷ /'ın.ţə.greı.ţıv/

combining two or more things in order to make them more effective:

- The new system will allow more efficient and integrative management of our data.
- Our patients might benefit if we took a more integrative approach to their care.





combining two or more things in order to make them more effective:

- The new system will allow more efficient and integrative management of our data.
- Our patients might benefit if we took a more integrative approach to their care.





combining two or more things in order to make them more effective: • The new system will allow more emclent and integrative management of our data.

- Our patients might benefit if we took a more integrative approach to their care.



STARTING WITH THE "HOW"

- Regression models

 - Can be penalized to reduce overfitting
 - Always interpretable





STARTING WITH THE "HOW"

• Regression models

- $\bullet \quad Y = \beta_0 + \beta_1 X_1 + \beta_2 X_2 + \dots + \beta_n X_n + \varepsilon$
- Can be penalized to reduce overfitting
- Always interpretable
- Decision trees
 - Can be combined in "forests" to reduce overfitting
 - Each tree contains random feature subsets
 - Large feature sets increase complexity
 - Becomes "blackbox" at scale



FITTING A LOGISTIC REGRESSION

Minimize the cost function

- $\sum_{i=1}^n (y_i \hat{y}_i)^2$
- Risk of overfitting
- Extend cost function with penalty term
 - $\sum_{i=1}^{n} (y_i \hat{y}_i)^2 + \lambda \sum_{j=1}^{p} \left| \hat{\beta}_j \right|$
 - λ is a tuning parameter
 - *p* is the number of predictors
 - Penalty term increases with many predictors and large coefficients



FITTING A RANDOM FOREST

Repeat N times

- Sample random subset of data
- Train decision tree on data subset
- Summarise decision trees by majority vote



THINGS TO CONSIDER

- Classification or regression
- Interpretability
- Model size
- Non-linear interactions
- Over-/Underfitting
- Computational costs





WHAT IS AVAILABLE?

- Clinical data age, sex, behaviour, comorbidities
- Genomics
- Epigenomics
- Microbiomics
- Lipidomics
- Proteomics
- Glycomics
- Transcriptomics
- Metabolomics

genomics

noun [U]

UK ◀୬ /dʒəˈnəʊm.iks/ US ◀୬ /dʒəˈnoʊm.iks/

the study of the genomes of living things:

• She is a specialist in animal genomics.







AALBORG UNIVERSITY



AALBORG UNIVERSITY





Monogenic effects

Polygenic effects

Combined effects

OTHER ASPECTS OF THE GENOME

- The Human Leukocyte Antigens (HLA)
 - 41560 alleles across 20 genes
- The Killer-cell Immunoglobin-like Receptors (KIR)
 - 2219 alleles across 17 genes





OTHER ASPECTS OF THE GENOME



OTHER ASPECTS OF THE GENOME

- Dark genomic regions
 - 36794 regions across 6054 genes



THINGS TO CONSIDER

- Genomics is a very broad term
- What is the technology underlying your data?
- What are the limitations of that technology?
- Is the immune system implicated?
- How much complexity have you removed to facilitate analysis?



ABSENCE CAD PREDICTION

Combining Polygenic and Proteomic Risk Scores With Clinical Risk Factors to Improve Performance for Diagnosing Absence of Coronary Artery Disease in Patients With de novo Chest Pain

Peter Loof Meller, MSc, Palle Duun Rohde, MSc, PhD, Jonathan Nørtoft Dahl, MD 🕲 , Laust Dupont Rasmussen, MD, PhD 🥥 , Samuel Emil Schmidt, MSc, PhD, Louise Nissen, MD, PhD, Victoria McGilligan, PhD 😳 , ... <u>show att</u> ... , and Mette Nyegaard, MSc, PhD 😨 🏾 🕇 <u>Author</u> INFO & AFFILIATIONS

Circulation: Genomic and Precision Medicine • Volume 16, Number 5 • https://doi.org/10.1161/CIRCGEN.123.004053

- GLMNET algorithm, combining ridge and lasso regularization
- Ensuring balanced dataset by focusing on CAD absence group
- Leveraging proteomics, genomics and clinical data
- Proteomics are age- and sex-corrected
- Finds proteomics to be ineffective
- PRS_{CAD} significantly improves prediction of CAD absence





ABSENCE CAD PREDICTION

RESEARCH ARTICLE | Originally Published 27 September 2023 |

Combining Polygenic and Proteomic Risk Scores With Clinical Risk Factors to Improve Performance for Diagnosing Absence of Coronary Artery Disease in Patients With de novo Chest Pain

Peter Loof Møller, MSc, Palle Duun Rohde, MSc, PhD, Jonathan Nørtoft Dahl, MD 💿 , Laust Dupont Rasmussen, MD, PhD 💿 , Samuel Emil Schmidt, MSc, PhD, Louise Nissen, MD, PhD, Victoria McGilligan, PhD 💿 , ... <u>show att</u> ... , and Mette Nyegaard, MSc, PhD 💿 🖾 | <u>author</u> <u>INFO & AFFILIATIONS</u>

Circulation: Genomic and Precision Medicine • Volume 16, Number 5 • https://doi.org/10.1161/CIRCGEN.123.004053



Research Open access Published: 20 March 2024

Predicting the presence of coronary plaques featuring high-risk characteristics using polygenic risk scores and targeted proteomics in patients with suspected coronary artery disease

Peter Loof Møller, Palle Duun Rohde, Jonathan Nørtoft Dahl, Laust Dupont Rasmussen, Louise Nissen Samuel Emil Schmidt, Victoria McGilligan, Daniel F. Gudbjartsson, Kari Stefansson, Hilma Holm, Jacob Fog Bentzon, Morten Bøttcher, Simon Winther & Mette Nyegaard ♡

Genome Medicine 16, Article number: 40 (2024) Cite this article

HIGH-RISK PLAQUE PREDICTION

- GLMNET algorithm
- Unbalanced dataset
- Leveraging proteomics, genomics and clinical data
- Proteomics are not age- and sex-corrected
- Estimates protein to be almost on par with clinical risk factor, but the combination does not improve prediction significantly



Research Open access Published: 20 March 2024

Predicting the presence of coronary plaques featuring high-risk characteristics using polygenic risk scores and targeted proteomics in patients with suspected coronary artery disease

Peter Loof Møller, Palle Duun Rohde, Jonathan Nørtoft Dahl, Laust Dupont Rasmussen, Louise Nissen Samuel Emil Schmidt, Victoria McGilligan, Daniel F. Gudbjartsson, Kari Stefansson, Hilma Holm, Jacot Fog Bentzon, Morten Bøttcher, Simon Winther & Mette Nyegaard ⊠

Genome Medicine 16, Article number: 40 (2024) Cite this article

HIGH-RISK PLAQUE PREDICTION

- GLMNET algorithm
- Unbalanced dataset
- Leveraging proteomics, genomics and clinical data
- Proteomics are not age- and sex-corrected
- Estimates protein to be almost on par with clinical risk factor, but the combination does not improve prediction significantly

Feature importance estimates



CONDITIONAL PGS APPLICATION

- PTP (clinical model) referral of women is no better than chance
- Age-wise analysis of models reveal PGS to be the best predictor in young people, especially women





CONDITIONAL PGS APPLICATION

CAD risk	Sex	Age	PTP*	RF-CL*	PGS*
	Female	<55	0 (0%)	0 (0%)	43 (12%)
High risk		≥55	156 (10%)	57 (7%)	136 (12%)
(>15%)	Male	<55	189 (12%)	100 (16%)	138 (18%)
		≥55	661 (22%)	404 (28%)	368 (31%)
	Female	<55	185 (5%)	53 (8%)	32 (3%)
Intermediate		≥55	484 (4%)	348 (7%)	227 (7%)
risk (5-15%)	Mala	<55	146 (10%)	172 (10%)	117 (5%)
	Mate	≥55	72 (10%)	307 (12%)	198 (13%)
	Famala	<55	97 (2%)	229 (3%)	207 (2%)
Low risk	Female	≥55	49 (2%)	284 (3%)	326 (2%)
(<5%)	Male	<55	60 (5%)	123 (5%)	140 (6%)
		≥55	0 (0%)	22 (9%)	167 (7%)

*Percentages denote the observed obstructive CAD prevalence within groups.

BREA

'n

AGENDA

12:30 – 12:45	Recap [Germline c	ancer genomics]
---------------	-------------------	-----------------

- **12:45 13:00** Break + questions
- **13:00 13:30** Lecture 1 [*Integrative genomics*]
- **13:30 13:40** Break
- **13:40 14:00** Discussion of article [*Multi-omic prediction of incident type 2 diabetes*]
- **14:00 14:20** Lecture 2 [*Multimodal data integration*]
- **14:20 14:30** Break
- **14:30 15:45** Group work + presentation
- 15:45 16:00 Evaluation at Moodle

MULTI-OMIC PREDICTION OF INCIDENDT TYPE 2 DIABETES



What is HbA1c and why do they use it for stratifying their cohort?



What is HbA1c and why do they use it for stratifying their cohort?

- Hemoglobin A1c
- Used for diagnosis and monitoring of diabetes patients
- Reflects average glucose levels over a longer period (10-12 weeks)
- ≥48 mmol/mol indicates diabetes
- ≥42 mmol/mol indicates prediabetes
- <42 mmol/mol indicates normoglycaemia</p>



Why is it valuable to identify individuals at risk of type 2 diabetes?



Why is it valuable to identify individuals at risk of type 2 diabetes?

• High prevalence of disease in the general population

• Early treatment reduces risk of complications

• Prediabetic individuals can often be "treated" with preventative behavioural interventions



Which type of omics would you prioritize, if you could only have one?





Looking at figure 3, could the researchers have done anything differently?

 "However, individuals at high predicted polygenic risk were at a substantially lower absolute risk than people with prediabetes, suggesting limited potential value in targeted genetic screening for preventative interventions"



AGENDA

- **12:30 12:45** Recap [Germline cancer genomics]
- **12:45 13:00** Break + questions
- **13:00 13:30** Lecture 1 [*Integrative genomics*]
- **13:30 13:40** Break
- **13:40 14:00** Discussion of article [*Multi-omic prediction of incident type 2 diabetes*]
- **14:00 14:20** Lecture 2 [Multimodal data integration]
- **14:20 14:30** Break
- **14:30 15:45** Group work + presentation
- **15:45 16:00**Evaluation at Moodle



MULTIMODAL DATA INTEGRATION

DATA SO FAR

• Tabular data

• Variables can be

PatientID	Gender	Age	Zip code	Test
55998	М	19	15723	Negative
88557	F	35	15674	Positive
55868	F	35	15674	Positive
44551	Μ	45	15623	Negative
58524	Μ	45	15623	Negative
25584	F	61	15633	Negative
58744	F	61	15643	Positive
87524	Μ	19	15762	Positive
87384	Μ	19	15762	Negative
17583	F	19	15762	Positive

 Table 1
 Sample medical dataset

M: male; F: female

DATA SO FAR

D	Tabular data	à
---	--------------	---

• Variables can be

• Continuous

PatientID	Gender	Age	Zip code	Test
55998	М	19	15723	Negative
88557	F	35	15674	Positive
55868	F	35	15674	Positive
44551	Μ	45	15623	Negative
58524	Μ	45	15623	Negative
25584	F	61	15633	Negative
58744	F	61	15643	Positive
87524	Μ	19	15762	Positive
87384	Μ	19	15762	Negative
17583	F	19	15762	Positive
M: mala: E: famala				

 Table 1
 Sample medical dataset

M: male; F: female



DATA SO FAR

		Tuble I Sumple medicul autuset				
		PatientID	Gender	Age	Zip code	Test
	Tabular data	55998	Μ	19	15723	Negative
		88557	F	35	15674	Positive
V	variables can be	55868	F	35	15674	Positive
	 Continuous 	44551	М	45	15623	Negative
	Categorical	58524	Μ	45	15623	Negative
		25584	F	61	15633	Negative
		58744	F	61	15643	Positive
		87524	М	19	15762	Positive
		87384	М	19	15762	Negative
		17583	F	19	15762	Positive

Table 1 Sample medical dataset

M: male; F: female

OTHER TYPES OF DATA

- Text Electronic health records
- Images CT/MRI scans
- Speech Operative dictation
- Video Endoscopy
- 3D scans Ultrasound

OTHER TYPES OF DATA

- Text Electronic health records
- Images CT/MRI scans
- Speech Operative I is it feasible to convert to tabular data?
 Video Endoscopy
- 3D scans Ultrasound

IMAGE ANALYSIS

nature > nature biomedical engineering > articles > article

Article | Published: 19 February 2018

Prediction of cardiovascular risk factors from retinal fundus photographs via deep learning

Ryan Poplin, Avinash V. Varadarajan, Katy Blumer, Yun Liu, Michael V. McConnell, Greg S. Corrado, Lily Peng ^I & Dale R. Webster

Nature Biomedical Engineering 2, 158–164 (2018) Cite this article

32k Accesses | 1209 Citations | 2335 Altmetric | Metrics





Five-year MACE prediction

lisk factor(s) or model used for the prediction	AUC (95% CI)
Age only	0.66 (0.61,0.71)
SBP only	0.66 (0.61,0.71)
3MI only	0.62 (0.56,0.67)
Sender only	0.57 (0.53,0.62)
Current smoker only	0.55 (0.52,0.59)
Ngorithm only	0.70 (0.65,0.74)
\ge + SBP + BMI + gender + current smoker	0.72 (0.68,0.76)
Ngorithm + age + SBP + BMI + gender + current smoker	0.73 (0.69,0.77)
SCORE ^{6,7}	0.72 (0.67,0.76)
Ngorithm + SCORE	0.72 (0.67,0.76)

FOUNDATION MODELS

Traditional ML



Massive external data

ullh

F

.



• Individual siloed models

- Require task-specific training
- Lots of human supervised training

• Massive multi-tasking model

Massive

Foundation

Model

.

Enterprise

proprietary data

- Adaptable with little or no training
- Pre-trained unsupervised learning

Q&A

Translation

Classification

Code Gen

 \checkmark

Prompting

Prompting

Fine

Tuned

Model

Perspective Published: 12 April 2023

Foundation models for generalist medical artificial intelligence

Michael Moor, Oishi Banerjee, Zahra Shakeri Hossein Abad, Harlan M. Krumholz, Jure Leskovec, Eric J. Topol ⊠ & Pranav Raipurkar ⊠

Nature 616, 259–265 (2023) Cite this article

a Bedside decision support



b Grounded radiology reports





most likely the aorta

(aortoduodenal fistula)

(() G E 5 3

FOUNDATION MODELS IN MEDICINE



Regulations: Application approval; validation; audits; community-based challenges; analyses of biases, fairness and diversity



FOUNDATION MODELS

Learning the natural history of human disease with generative transformers

Artem Shmatko^{1,2,3*}, Alexander Wolfgang Jung^{2,4,5*}, Kumar Gaurav^{2*}, Søren Brunak⁴, Laust Mortensen⁵, Ewan Birney^{2#}, Tom Fitzgerald^{2#} and Moritz Gerstung^{1,2,6,7,8,9#}



Input: Age: Token 0.0: Male 2.0: B01 Varicella [chickenpox] 3.0: L20 Atopic dermatitis 5.0: No event 10.0 No event 15.0: No event 20.0: No event 20.0: G43 Migraine 21.0: E73 Lactose intolerance 22.0 B27 Infectious mononucleosis 25.0. No event 28.0: J11 Influenza, virus not identified 30.0: No event 35.0: No event 40.0: No event 41.0: Smoking low 410 BMI mid 410. Alcohol low 42.0. No event

Output:

43.2: No event 43.5: M54 Dorsalgia 44.6: I86 Varicose veins of other sites 50.4: K52 Other non-infective gastro-enteritis and colitis 52.2: H83 Other diseases of inner ear 53.9: J22 Unspecified acute lower respiratory infection 54.5: L30 Other dermatitis 55.3: No event 57.5: L50 Urticaria 59.4: K62 Other diseases of anus and rectum 69.8: J90 Pleural effusion, not elsewhere classified 70.0: K21 Gastro-oesophageal reflux disease 70.1: K76 Other diseases of liver 70.3: I10 Essential primary hypertension 70.4: M85 Other disorders of bone density and structure 70.7: M81 Osteoporosis without pathological fracture 71.2: J98 Other respiratory disorders 72.1: J80 Adult respiratory distress syndrome 72.2: No event 72.7: Death

PAGE

54

BREA

'n

AGENDA

- **12:30 12:45** Recap [Germline cancer genomics]
- **12:45 13:00** Break + questions
- **13:00 13:30** Lecture 1 [*Integrative genomics*]
- **13:30 13:40** Break
- **13:40 14:00** Discussion of article [*Multi-omic prediction of incident type 2 diabetes*]
- **14:00 14:20** Lecture 2 [*Multimodal data integration*]
- **14:20 14:30** Break
- **14:30 15:45** Group work + presentation
- **15:45 16:00**Evaluation at Moodle



GROUP WORK

Make groups of three-four individuals

 For your type of "omics", give a short presentation of the methodology and perspectives, considering the following:

 How does the method work?
 How much data is generated?
 Why is this type of data interesting?
 Does it interact with other "omics"?

2) Presentation [5-7 min per group]



TYPES OF "OMICS"

- Proteomics
- Metabolomics
- Microbiomics
- Epigenomics
- Lipidomics
- Glycomics
- Transcriptomics



YOUR OPPINION MATTERS



List the two Art X most important things you learned today	What did you find difficult?	What did you find easy?	Improvements for the formext session?	
			+	
+				

